富国中证医药50ETF联接C(012802)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
9,324,035.77 |
4,604,595.54 |
-21,692,451.23 |
-32,463,738.26 |
| 利息合计 |
6,353.60 |
3,537.23 |
17,784.92 |
7,737.10 |
| 其中：存款利息收入 |
6,353.60 |
3,537.23 |
17,784.92 |
7,737.10 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-11,784,554.37 |
-9,675,259.86 |
-40,286,222.17 |
-16,387,224.24 |
| 其中：股票投资收益 |
94,519.96 |
72,178.72 |
46,042.23 |
-71,944.62 |
| 基金投资收益 |
-11,954,810.31 |
-9,781,385.33 |
-40,426,770.65 |
-16,386,124.42 |
| 债券投资收益 |
70,395.95 |
29,861.84 |
85,484.36 |
62,675.47 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
5,340.03 |
4,084.91 |
9,021.89 |
8,169.33 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
21,046,319.35 |
14,260,240.93 |
18,472,933.31 |
-16,128,998.09 |
| 其他收入 |
55,917.19 |
16,077.24 |
103,052.71 |
44,746.97 |
| 费用 |
274,172.90 |
134,178.07 |
279,612.50 |
142,361.19 |
| 管理人报酬 |
37,713.63 |
19,190.86 |
41,530.40 |
21,549.73 |
| 基金托管费 |
7,542.80 |
3,838.19 |
8,306.06 |
4,309.94 |
| 销售服务费 |
61,857.19 |
30,927.13 |
72,245.35 |
38,123.27 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
9,892.03 |
2,074.79 |
- |
- |
| 其中：卖出回购金融资产支出 |
9,892.03 |
2,074.79 |
- |
- |
| 其他费用 |
157,167.25 |
78,147.10 |
157,530.69 |
78,378.25 |
| 利润总额 |
9,049,862.87 |
4,470,417.47 |
-21,972,063.73 |
-32,606,099.45 |
微信公众号
证券之星APP
基本资料
